title: [PDE5 inhibitors in treatment of benign prostatic syndrome].
authors.affiliation: Bayer Health CareAG & Bayer Vital, 42096 Wuppertal. peter.sandner@bayerhealthcare.com
authors.forename: P
authors.initials: P
authors.lastname: Sandner
authors.forename: H
authors.initials: H
authors.lastname: Tinel
authors.forename: B
authors.initials: B
authors.lastname: Stelte-Ludwig
authors.forename: J
authors.initials: J
authors.lastname: Huetter
authors.forename: D
authors.initials: D
authors.lastname: Neuser
authors.forename: E
authors.initials: E
authors.lastname: Bischoff
authors.forename: E
authors.initials: E
authors.lastname: Ulbrich
mesh_terms: D000818:Animals; D002243:Carbolines / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007537:Isometric Contraction / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000187:drug effects; D009924:Organ Culture Techniques; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011467:Prostate / Q000187:drug effects; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011687:Purines / Q000627:therapeutic use; D051381:Rats; D000068677:Sildenafil Citrate; D017154:Stromal Cells / Q000187:drug effects; D013450:Sulfones / Q000627:therapeutic use*; D013577:Syndrome; D000068581:Tadalafil; D014227:Triazines / Q000627:therapeutic use; D014521:Urethra / Q000187:drug effects; D001743:Urinary Bladder / Q000187:drug effects; D000069058:Vardenafil Dihydrochloride
chemical_list: D002243:Carbolines; D007093:Imidazoles; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate